

RECEIVED
JAN 31 2000

4012-113 DIV. 1
PATENT APPLICATION

JP 19/15
#15
LB
7/7/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

Applicant: Ekwuribe et al.

Serial No.: 09/429,798

Date Filed: October 29, 1999

Title: Blood-Brain Barrier Therapeutics

Examiner: Not Yet Assigned

Group Art Unit: 1615

FIRST CLASS MAILING CERTIFICATE

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, under the provisions of 37 CFR 1.8.

Jacqueline Bagwell
Jacqueline Bagwell

January 19, 2000
Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Supplemental Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from the U.S. International Searching

Authority in a counterpart international application not more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- ☐ b. I hereby certify that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Supplemental Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$130.00 in payment of the petition fee under 37 C.F.R. §1.17(i)(1). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



William A. Barrett
Registration No. 42,296

**INTELLECTUAL PROPERTY/
TECHNOLOGY LAW**
P.O. Box 14329
Research Triangle Park, NC 27709
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4012-113 DIV 1

(use several sheets if necessary)

October 29, 1999

09/429,798

1615

**EXAMINER
INITIAL**


PATENT
NUMBER

ISSUE DATE

NAME _____

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE

**DOCUMENT
NUMBER**

PUBLICATION
DATE

COUNTRY

CLAS

SUBCLASS

TRANSLATION
YES | NO

AA

WO
93/01802

Feb 4, 93

PCT

	X
--	---

AB

Delgado et al. "The Uses and Properties of PEG-Linked Proteins". *Critical Review in Therapeutic Drug Carrier Systems*, 9(3, 4):249-304 (1992).

Continue on Page

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.